Navigation Links
Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods
Date:11/20/2008

CAMBRIDGE, England, November 20 /PRNewswire-FirstCall/ -- Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, has signed a Master Service Agreement of up to five years with Pfizer Limited, the UK operating unit of the global research-based pharmaceutical company Pfizer, Inc. (NYSE: PFE). Under the terms of the agreement, SCS will provide research services, cell lines, media and reagents to support Pfizer's R&D efforts in this important field.

Dr Alastair Riddell, CEO of SCS, said, "The opening of Pfizer's new regenerative medicine research facility in Cambridge, UK, last week is very important for stem cell research and reinforces the UK's position as an international centre of excellence. We are therefore very pleased to be able to support Pfizer's efforts to advance biomedical research under our new agreement."

The Pfizer regenerative medicine unit will be led by Chief Scientific Officer, Ruth McKernan, PhD, who said, "I'm very excited to lead this new research unit. While there is still a lot to understand about how stem cells can be used therapeutically, we believe it is one of the most promising areas of scientific research. Building successful partnerships with companies such as Stem Cell Sciences will be important for us."

About Stem Cell Sciences plc

Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is now focussing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies.

Stem Cell Sciences has a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. The Company has been active in the stem cell research field since 1994, principally focused on technologies to grow, differentiate, and purify adult and embryonic stem cells. These include technologies to permit the generation of highly purified stem cells and their differentiated progeny (specialised tissue cell types) for use in genetic, pharmacological and toxicological screens. Moreover, these technologies may be able to provide pure populations of appropriate cell types for transplantation therapies in the future.

The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash near Melbourne, Australia and a business development office in San Francisco, USA.

For further information on the company please visit: http://www.stemcellsciences.com.

    For further information, please contact:

    Stem Cell Sciences plc (United Kingdom),
    Alastair Riddell, CEO,
    Tim Allsopp, Chief Scientific Officer,
    +44(0)1223-499160;

    Stem Cell Sciences pty ltd (Australia),
    Paul Bello, Operations Manager,
    +61(0)400-500-495;

    Citigate Dewe Rogerson (For SCS, UK),
    Mark Swallow / Emma Palmer Foster / Amber Bielecka,
    +44(0)20-7638-9571;

    Talk Biotech (For SCS, Australia),
    Fay Weston, Director,
    +61(0)422-206-036;

    Daniel Stewart & Company (NOMAD to SCS, UK),
    Simon Leathers / Simon Starr,
    +44(0)207-776-6566


'/>"/>
SOURCE Stem Cell Sciences plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. BBM Announces Offer to Acquire YM BioSciences Inc.
3. Human Pheromone Sciences Announces Third Quarter Results
4. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
5. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
6. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
7. Stem Cell Sciences Enters into Services Agreement with Huntingdons Disease Research Group, CHDI Foundation Inc.
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
9. Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
10. Advanced Life Sciences Announces Third Quarter 2008 Financial Results
11. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... EDISON, N.J. , Feb. 4, 2016 ... company focused on the development and commercialization of targeted ... BIO CEO & Investor Conference 2016, to be held ... and Source Capital Group,s 2016 Disruptive Growth & Healthcare ... on February 10-11, 2016. James Sapirstein ...
(Date:2/4/2016)... , February 4, 2016 ... Laboratories (ABL), Inc. --> Strasbourg, France ... --> PharmaVentures is pleased to announce that it ... its biopharmaceutical manufacturing unit in Strasbourg, France ... --> --> Transgene (Euronext: ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... a new office dedicated to the North American healthcare market. , Aerocom Healthcare, ... healthcare facilities. The company will provide new pneumatic tube systems or expand ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):